Group 1 - The acquisition involves a total consideration of RMB 270 million, with the target company becoming a wholly-owned subsidiary of the acquiring company after the transaction [1] - The target company specializes in clinical trial technology services and related laboratory services, enhancing the acquiring company's global laboratory service capabilities and influence in China [2] - The acquisition is expected to strengthen the acquiring company's position as a trusted partner in the clinical research industry by expanding its center laboratory services in China and the Asia-Pacific region [2] Group 2 - The target group has extensive experience supporting over 1,500 clinical trials across multiple therapeutic areas and is known for its compliance with Good Clinical Practice (GCP) [2] - The acquisition will enhance the ability to provide high-quality one-stop services to pharmaceutical companies, contract research organizations, and research institutions [2] - The target company's successful track record includes contributions to the successful launch of 35 new drugs and support for regulatory audits [2]
方达控股拟2.7亿元收购上海观合医药科技股份有限公司以提升全球实验室服务能力